TY - BOOK ID - 126294713 TI - Anticancer Drugs 2021 AU - Meegan, Mary J AU - O'Boyle, Niamh M PY - 2022 PB - Basel MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - Research & information: general KW - Chemistry KW - thymidylate synthase KW - cytotoxicity KW - 1,2,3-triazole KW - 1,3,4-oxadiazole KW - 5-fluoruracil KW - pemetrexed KW - docking KW - 3,4′-bis-guanidino KW - 3-amino-4′-guanidino KW - diphenyl ether KW - phenyl pyridyl ether KW - intramolecular hydrogen bond KW - cancer cell viability KW - HL-60 KW - BRAF KW - apoptosis KW - thieno[2,3-d][1,2,3]triazine KW - acetamide KW - H1299 KW - HER2 KW - EGFR KW - Bcl-2 inhibitors KW - Indole-based analogues KW - benzimidazole KW - MTT cytotoxic assay KW - cell cycle analysis KW - DNA fragmentation KW - ELISA KW - solid/lipid nanoparticles KW - phenstatin KW - letrozole KW - tubulin polymerisation inhibitor KW - aromatase inhibitor KW - breast cancer KW - hybrid molecule KW - dual-targeting molecule KW - designed multiple ligand KW - NaMSA KW - cyclophosphamide KW - histopathology KW - testis KW - urinary bladder KW - anticancer agents KW - enantioselective synthesis KW - gastric adenocarcinoma KW - tryptophanol KW - concentration-guided dosing KW - model informed dosing KW - physiologically based pharmacokinetics KW - sorafenib KW - tyrosil-DNA-phosphodiesterase 1 KW - adamantane KW - resin acid KW - TDP1 KW - cytotoxic agents KW - apoptosis induction KW - HT-29 cells KW - MDA-MB-231 cells KW - mechanism prediction KW - STAT inhibitors KW - miR-21 KW - hydrazide derivatives KW - nitrogen scaffolds KW - mitoxantrone KW - cardiotoxicity KW - inflammation KW - oxidative stress KW - age KW - cumulative dose KW - Trk KW - NTRK KW - tissue-agnostic KW - larotrectinib KW - entrectinib KW - Trk fusion KW - protein kinase inhibitors KW - USFDA KW - cancer KW - patent review KW - generic product KW - doxazosin KW - MD simulations KW - combretastatin A-4 KW - cytotoxic activity KW - hybrid compounds KW - indazole KW - mucin KW - MUC1 KW - MUC16 KW - immunotherapy KW - cancer vaccine KW - CAR (chimeric antigen receptor) KW - ADC (antibody-drug conjugate) KW - thiourea KW - interleukin-6 KW - trypan blue assay KW - chalcones KW - exportin-1 KW - covalent binding KW - CovDock KW - anticancer activity KW - xanthone KW - in vitro KW - in vivo KW - isolation KW - synthesis KW - heterocyclic compound KW - benzenesulfonamides KW - imidazoles KW - alkylated KW - colony formation KW - tumor spheroids KW - HDAC inhibitors KW - chalcone KW - dual inhibitors KW - carvedilol KW - kidney KW - toxicity KW - 7-deaza-4′-thioadenosine derivatives KW - multi-kinase inhibitor KW - anticancer KW - nucleoside KW - Imiquimod KW - drug efflux KW - multidrug resistance KW - Toll-Like Receptor KW - n/a KW - 3,4'-bis-guanidino KW - 3-amino-4'-guanidino KW - 7-deaza-4'-thioadenosine derivatives UR - https://www.unicat.be/uniCat?func=search&query=sysid:126294713 AB - The Special Issue "Anticancer Drugs 2021" of Pharmaceuticals is focused on recent significant advances in the design, synthesis, molecular mechanism of action and therapeutic applications of anticancer drugs. This collection of preclinical research papers and reviews includes designed chemotherapeutic agents, targeted therapies and biological agents. The rationalization for the biological activity of these drugs is presented, which helps to guide the design of more effective agents. Structure–activity relationships, together with the biological context in which targets are selected for oncology drug development, are also considered. ER -